Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

N/ACompletedNCT02201550

Hvidovre University Hospital9 enrolled

Overview

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes. The hypotheses are: * Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood * Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood * Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Study Type

OBSERVATIONAL

Enrollment

Conditions

Type 2 Diabetes Mellitus

Eligibility

Sex: MALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * BMI \> 27 kg/m2 * Planed start of treatment with liraglutide * Age \> 18 years Exclusion Criteria: * Infection or active inflammatory disorder * Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids) * Smoking * Alcohol consumption \> 14 beverages/week * Former bariatric surgery

Locations (1)

Hvidovre University Hospital

Hvidovre, Denmark

Outcomes

Primary Outcomes

Change in number of specific immune cells in blood detected by flow cytometry

Time frame: Before and 12 weeks after initiation of liraglutide treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.